MC, S., & WS, R. (2024). Clinical Outcomes After Personalized Dosimetry for 90Y Radioembolization of Advanced Hepatocellular Carcinoma: Defining the Role of a Device in a Pharma-Centric Landscape. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 65(2), 270. https://doi.org/10.2967/jnumed.123.267035
Chicago Style (17th ed.) CitationMC, Soulen, and Rilling WS. "Clinical Outcomes After Personalized Dosimetry for 90Y Radioembolization of Advanced Hepatocellular Carcinoma: Defining the Role of a Device in a Pharma-Centric Landscape." Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine 65, no. 2 (2024): 270. https://doi.org/10.2967/jnumed.123.267035.
MLA (9th ed.) CitationMC, Soulen, and Rilling WS. "Clinical Outcomes After Personalized Dosimetry for 90Y Radioembolization of Advanced Hepatocellular Carcinoma: Defining the Role of a Device in a Pharma-Centric Landscape." Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine, vol. 65, no. 2, 2024, p. 270, https://doi.org/10.2967/jnumed.123.267035.
